探究重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的治疗效果
合集下载
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
To Explore the Therapeutic Effect of Recombinant Human Brain Natriuretic Peptide on Acute Decompensated Severe Patients with Chronic Heart Failure
XU Xiao-bo1, WU Tian-tian2 1. Coronary Heart Disease intensive Care Unit, Xuchang City Central Hospital, Xuchang Henan 461000, China; 2. Department of Cardiology, Xuchang Hospital, Xuchang Henan 461000, China [Abstract] Objective: To investigate the therapeutic effect of recombinant human brain natriuretic peptide on acute decompensated severe patients with chronic heart failure. Methods: 120 patients with acute decompensated(ADHF)from May 2016 to August 2017 were randomly divided into two groups: 60 cases each. The control group was treated with milrinone and the observation group with recombinant human brain natriuretic peptide. Results: There was no significant difference in peripheral edema, dyspnea and lung rale score between the two groups before treatment. The total effective rate of treatment in the observation group was higher than that in the control group, the incidence of adverse reactions in the observation group was lower than that in the control group, and the difference between the two groups was significant(P<0.05). Conclusion: Recombinant human brain natriuretic peptide is effective in the treatment of acute decompensated severe patients with chronic heart failure. It can improve the symptoms of dyspnea and cardiac function, and has a significant effect on correcting the symptoms of heart failure. [Key words] Recombinant Human Brain Natriuretic Peptide; Acute Decompensation of Chronic Heart Failure; Therapeutic Effect
Drugs and Clinic 药物与临床
探究重组人脑钠肽治疗慢性心力Байду номын сангаас竭急性失代偿性重症
患者的治疗效果
徐晓波1，吴田田2 1.河南省许昌市中心医院冠心病重症监护室(CCU)，河南 许昌 461000；2.河南省许昌市立医院心内科，河南 许昌 461000 [摘要] 目的：探究重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的治疗效果。方法：选取我院2016年5月至2017年8月期间收治 的120例慢性心力衰竭急性失代偿性重症(ADHF)患者为研究对象，将其随机分成两组，各60例。对照组使用米力农治疗，观察组使用重组 人脑钠肽治疗，比较两组的治疗效果。结果：两组患者治疗前的周身水肿、呼吸困难、肺部啰音评分相较无较大的差异，治疗后两组评分 均有改善但观察组的改善程度比对照组好；观察组的治疗总有效率高于对照组；观察组的不良反应发生率低于对照组，两组间比较差异较 大(P<0.05)有统计学意义。结论：重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的效果良好，能改善患者呼吸困难等症状及心功 能，对纠正心衰症状效果显著。 [关键词] 重组人脑钠肽；慢性心力衰竭急性失代偿性；治疗效果 [中图分类号] R972 [文献标识码] A [文章编号] 1672-2809(2019)05-0031-04
作者简介：徐晓波，主要主要从事心血管内科疾病诊治与 研究工作。E-mail：2158945366@
急性失偿性心力衰竭(Acute Decompensation of Heart Failure, ADHF)由慢性心力衰竭发 生而来，此类患者较多，约占所有心力衰竭患者的 3/4[1]。临床上以呼吸困难、血压下降、肺水肿、昏 迷、嗜睡、咳血等为主要表现[2]，此病的死亡率、再 住院率极高，严重威胁患者的生命健康。临床上治 疗ADHF多使用利尿剂、血管扩张剂、正性肌力药物 等，但药效不能有效达到抗心力衰竭的标准[3]。随着 医疗技术的进展，重组人脑钠肽是治疗心力衰竭的热 门药物，其在临床上已得到广泛应用。本次我院为探 究重组人脑钠肽的具体疗效进行了研究，将之与米力 农相比较，发现前者效果好于后者，具体分析如下：
XU Xiao-bo1, WU Tian-tian2 1. Coronary Heart Disease intensive Care Unit, Xuchang City Central Hospital, Xuchang Henan 461000, China; 2. Department of Cardiology, Xuchang Hospital, Xuchang Henan 461000, China [Abstract] Objective: To investigate the therapeutic effect of recombinant human brain natriuretic peptide on acute decompensated severe patients with chronic heart failure. Methods: 120 patients with acute decompensated(ADHF)from May 2016 to August 2017 were randomly divided into two groups: 60 cases each. The control group was treated with milrinone and the observation group with recombinant human brain natriuretic peptide. Results: There was no significant difference in peripheral edema, dyspnea and lung rale score between the two groups before treatment. The total effective rate of treatment in the observation group was higher than that in the control group, the incidence of adverse reactions in the observation group was lower than that in the control group, and the difference between the two groups was significant(P<0.05). Conclusion: Recombinant human brain natriuretic peptide is effective in the treatment of acute decompensated severe patients with chronic heart failure. It can improve the symptoms of dyspnea and cardiac function, and has a significant effect on correcting the symptoms of heart failure. [Key words] Recombinant Human Brain Natriuretic Peptide; Acute Decompensation of Chronic Heart Failure; Therapeutic Effect
Drugs and Clinic 药物与临床
探究重组人脑钠肽治疗慢性心力Байду номын сангаас竭急性失代偿性重症
患者的治疗效果
徐晓波1，吴田田2 1.河南省许昌市中心医院冠心病重症监护室(CCU)，河南 许昌 461000；2.河南省许昌市立医院心内科，河南 许昌 461000 [摘要] 目的：探究重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的治疗效果。方法：选取我院2016年5月至2017年8月期间收治 的120例慢性心力衰竭急性失代偿性重症(ADHF)患者为研究对象，将其随机分成两组，各60例。对照组使用米力农治疗，观察组使用重组 人脑钠肽治疗，比较两组的治疗效果。结果：两组患者治疗前的周身水肿、呼吸困难、肺部啰音评分相较无较大的差异，治疗后两组评分 均有改善但观察组的改善程度比对照组好；观察组的治疗总有效率高于对照组；观察组的不良反应发生率低于对照组，两组间比较差异较 大(P<0.05)有统计学意义。结论：重组人脑钠肽治疗慢性心力衰竭急性失代偿性重症患者的效果良好，能改善患者呼吸困难等症状及心功 能，对纠正心衰症状效果显著。 [关键词] 重组人脑钠肽；慢性心力衰竭急性失代偿性；治疗效果 [中图分类号] R972 [文献标识码] A [文章编号] 1672-2809(2019)05-0031-04
作者简介：徐晓波，主要主要从事心血管内科疾病诊治与 研究工作。E-mail：2158945366@
急性失偿性心力衰竭(Acute Decompensation of Heart Failure, ADHF)由慢性心力衰竭发 生而来，此类患者较多，约占所有心力衰竭患者的 3/4[1]。临床上以呼吸困难、血压下降、肺水肿、昏 迷、嗜睡、咳血等为主要表现[2]，此病的死亡率、再 住院率极高，严重威胁患者的生命健康。临床上治 疗ADHF多使用利尿剂、血管扩张剂、正性肌力药物 等，但药效不能有效达到抗心力衰竭的标准[3]。随着 医疗技术的进展，重组人脑钠肽是治疗心力衰竭的热 门药物，其在临床上已得到广泛应用。本次我院为探 究重组人脑钠肽的具体疗效进行了研究，将之与米力 农相比较，发现前者效果好于后者，具体分析如下：